A new antigen SUMI carried on glycophorin A encoded by the GYPA*M with c.91A>C (p.Thr31Pro) belongs to the MNS blood group system.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
27
08
2019
revised:
19
03
2020
accepted:
23
03
2020
pubmed:
3
5
2020
medline:
22
6
2021
entrez:
3
5
2020
Statut:
ppublish
Résumé
MNS is one of the highly polymorphic blood groups comprising many antigens generated by genomic recombination among the GYPA, GYPB, and GYPE genes as well as by single-nucleotide changes. We report a patient with red blood cell (RBC) antibody against an unknown low-frequency antigen, tentatively named SUMI, and investigated its carrier molecule and causal gene. Standard serologic tests, including enzyme tests, were performed. Monoclonal anti-SUMI-producing cells (HIRO-305) were established by transformation and hybridization methods using lymphocytes from a donor having anti-SUMI. SUMI+ RBCs were examined by immunocomplex capture fluorescence analysis (ICFA) using HIRO-305 and murine monoclonal antibodies against RBC membrane proteins carrying blood group antigens. Genomic DNA was extracted from whole blood, and the GYPA gene was analyzed by polymerase chain reactions and Sanger sequencing. Serologic screening revealed that 23 of the 541,522 individuals (0.0042%) were SUMI+, whereas 1351 of the 10,392 individuals (13.0%) had alloanti-SUMI. SUMI antigen was sensitive to ficin, trypsin, pronase, and neuraminidase, but resistant to α-chymotrypsin and sulfydryl-reducing agents. ICFA revealed that the SUMI antigen was carried on glycophorin A (GPA). According to Sanger sequencing and cloning, the SUMI+ individuals had a GYPA*M allele with c.91A>C (p.Thr31Pro), which may abolish the O-glycan attachment site. The new low-frequency antigen SUMI is carried on GPA encoded by the GYPA*M allele with c.91A>C (p.Thr31Pro). Neuraminidase sensitivity suggests that glycophorin around Pro31 are involved in the SUMI determinant.
Sections du résumé
BACKGROUND
MNS is one of the highly polymorphic blood groups comprising many antigens generated by genomic recombination among the GYPA, GYPB, and GYPE genes as well as by single-nucleotide changes. We report a patient with red blood cell (RBC) antibody against an unknown low-frequency antigen, tentatively named SUMI, and investigated its carrier molecule and causal gene.
STUDY DESIGN AND METHODS
Standard serologic tests, including enzyme tests, were performed. Monoclonal anti-SUMI-producing cells (HIRO-305) were established by transformation and hybridization methods using lymphocytes from a donor having anti-SUMI. SUMI+ RBCs were examined by immunocomplex capture fluorescence analysis (ICFA) using HIRO-305 and murine monoclonal antibodies against RBC membrane proteins carrying blood group antigens. Genomic DNA was extracted from whole blood, and the GYPA gene was analyzed by polymerase chain reactions and Sanger sequencing.
RESULTS
Serologic screening revealed that 23 of the 541,522 individuals (0.0042%) were SUMI+, whereas 1351 of the 10,392 individuals (13.0%) had alloanti-SUMI. SUMI antigen was sensitive to ficin, trypsin, pronase, and neuraminidase, but resistant to α-chymotrypsin and sulfydryl-reducing agents. ICFA revealed that the SUMI antigen was carried on glycophorin A (GPA). According to Sanger sequencing and cloning, the SUMI+ individuals had a GYPA*M allele with c.91A>C (p.Thr31Pro), which may abolish the O-glycan attachment site.
CONCLUSIONS
The new low-frequency antigen SUMI is carried on GPA encoded by the GYPA*M allele with c.91A>C (p.Thr31Pro). Neuraminidase sensitivity suggests that glycophorin around Pro31 are involved in the SUMI determinant.
Substances chimiques
GYPA protein, human
0
Glycophorins
0
MNSs Blood-Group System
0
Types de publication
Case Reports
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1287-1293Informations de copyright
© 2020 AABB.
Références
The International Society of Blood Transfusion: red cell immunogenetics and blood group terminology working party. Amsterdam: ISBT Central Office; [cited 2020 Apr 27]. Available from: https://www.isbtweb.org/fileadmin/user_upload/Table_of_blood_group_antigens_within_systems_v9_12th_July_2019.
Chasis JA, Mohandas N. Red blood cell glycophorins. Blood 1992;80:1869-79.
Ugorski M, Blackall DP, Påhlsson P, et al. Recombinant Miltenberger I and II human blood group antigens: the role of glycosylation in cell surface expression and antigenicity of glycophorin A. Blood 1993;82:1913-20.
DuPont BR, Grant SG, Oto SH, et al. Molecular characterization of glycophorin A transcripts in human erythroid cells using RT-PCR, allele-specific restriction, and sequencing. Vox Sang 1995;68:121-8.
Uchikawa M, Tsuneyama H, Ogasawara K, et al. Molecular basis for a novel low-frequency antigen in the MNS blood group system, Td. Vox Sang 2006;9(Suppl 3):133.
Daniels G. Human blood groups. 3rd ed. Oxford: Wiley-Blackwell; 2013. p. 96-161.
Neppert J. Blood group antibody anti-Mg and isoagglutinin frequency in the Republic of Liberia, West Africa. Transfusion 1980;20:448-9.
Daniels G. Effect of enzymes on and chemical modifications of high-frequency red cell antigens. Immunohematology 1992;8:53-7.
III-E. Treating RBCs with neuraminidase (T-activation). In: Judd WJ, Johnson ST, Storry JR, editors. Juddʼs methods in immunohematology. 3rd ed. Bethesda (MD): AABB Press; 2008.
Toyoda C, Suzuki Y, Tsuneyama H, et al. Production of human monoclonal anti-Jk3, recognizing an epitope including the Jka/Jkb polymorphic site of the Kidd glycoprotein. Transfus Med 2014;24:286-91.
Fujiwara K, Shimano K, Tanaka H, et al. Application of bead array technology to simultaneous detection of human leukocyte antigen and human platelet antigen antibodies. Vox Sang 2009;96:244-51.
Ogasawara K, Sasaki K, Isa K, et al. Weak D alleles in Japanese: a c.960G>A silent mutation in exon 7 of the RHD gene that affects D expression. Vox Sang 2016;110:179-84.
Roback JD, Combs MR, Grossman BJ, et al., editors. Method 2-8. Testing saliva for A, B, H, Lea, and Leb antigens. In: Roback JD, Combs MR, Grossman BJ, et al., editors. Technical manual. 16th ed. Bethesda (MD): AABB; 2008.
Kurita R, Suda N, Sudo K, et al. Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. PLoS One 2013;8:e59890.
Roback JD, Combs MR, Grossman BJ, et al. Method 3-8. Using sulfhydryl reagents to distinguish IgM from IgG antibodies. In: Technical Manual. 16th ed. Bethesda (MD): AABB; 2008.
Zelinski T, Coghlan G, Liu XQ, et al. ABCG2 null alleles define the Jr(a−) blood group phenotype. Nat Genet 2012;44:131-2.
Storry JR, Joud M, Christophersen MK, et al. Homozygosity for a null allele of SMIM1 defines the Vel-negative blood group phenotype. Nat Genet 2013;45:537-41.
McBean RS, Hyland CA, Hendry JL, et al. SARA: a “new” low-frequency MNS antigen (MNS47) provides further evidence of the extreme diversity of the MNS blood group system. Transfusion 2015;55:1451-6.
Omae Y, Ito S, Takeuchi M, et al. Integrative genome analysis identified the KANNO blood group antigen as prion protein. Transfusion 2019;59:2429-35.
Petty AC, Green CA, Daniels GL. The monoclonal antibody-specific immobilization of erythrocyte antigens assay (MAIEA) in the investigation of human red-cell antigens and their associated membrane proteins. Transfus Med 1997;7:179-88.
Tsuneyama H, Uchikawa M, Matsubara M, et al. Molecular basis of Or in the MNS blood group system. Vox Sang 1998;74(Suppl 1):1446.
Reid ME, Sausais L, Øyen R, et al. First example of hemolytic disease of the newborn caused by anti-Or and confirmation of the molecular basis of Or. Vox Sang 2000;79:180-2.
Tomita M, Marchesi VT. Amino-acid sequence and oligosaccharide attachment sites of human erythrocyte. Proc Natl Acad Sci U S A 1975;72:2964-8.
Pisano A, Redmond W, Williams KL, et al. Glycosylation sites identified by solid-phase Edman degradation: O-linked glycosylation motifs on human glycophorin A. Glycobiology 1993;3:429-35.